Predictors of new onset of diabetes after transplantation in stable renal recipients

Nephron - Clinical Practice

Volumn 110, Issue 1, 2008, Pages

  Shehab Eldin, Walid ^a   Shoker, Ahmed ^a,b  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Insulin resistance; New onset of diabetes after transplantation; Renal transplant

Indexed keywords

ADIPONECTIN; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; MALONALDEHYDE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PROINSULIN; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GRAFT RECIPIENT; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEW ONSET OF DIABETES AFTER TRANSPLANTATION; PANCREAS ISLET BETA CELL; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK FACTOR; UNIVARIATE ANALYSIS;

ADULT; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; INSULIN RESISTANCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TACROLIMUS;

EID: 47649123540     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000148207     Document Type: Article

References (36)

1. Kes P, Brunetta B, Basic-Jukic N: Cardiovascular diseases after kidney transplantation (in Croatian) Lijec Vjesn 2006;128:228-232.
2. Faenza A, Fuga G, Nardo B, Donati G, Cianciolo G, Scolari MP, Stefoni S: Metabolic syndrome after kidney transplantation. Transplant Proc 2007;39:1843-1846.
3. Gonzalez-Posada JM, Hernandez D, Genis BB, Tamajon LP, Perez JG, Maceira B, Sanchez MR, Seron D: Increased cardiovascular risk profile and mortality in kidney allograft recipients with post-transplant diabetes mellitus in Spain. Clin Transplant 2006;20:650-658.
4. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ: Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003;3:178-185.
5. Schiel R, Heinrich S, Steiner T, Ott U, Stein G: Post-transplant diabetes mellitus: risk factors, frequency of transplant rejections, and long-term prognosis. Clin Exp Nephrol 2005;9:164-169.
6. Joss N, Staatz CE, Thomson AH, Jardine AG: Predictors of new onset diabetes after renal transplantation. Clin Transplant 2007;21:136-143.
7. Rodrigo E, Fernandez-Fresnedo G, Valero R, Ruiz JC, Pinera C, Palomar R, Gonzalez-Cotorruelo J, Gomez-Alamillo C, Arias M: New-onset diabetes after kidney transplantation: risk factors. J Am Soc Nephrol 2006;17:S291-S295.
8. American Diabetes Association: Clinical Practice Recommendations. Diabetes Care 2007;30.
9. Prasad K: Hypocholesterolemic and antiatherosclerotic effect of flax lignan complex isolated from flaxseed. Atherosclerosis 2005;179:269-275.
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
11. Porte D Jr, Kahn SE: Hyperproinsulinemia and amyloid in NIDDM. Clues to etiology of islet β-cell dysfunction? Diabetes 1989;38:1333-1336.
12. Roozbeh J, Mehdizadeh AR, Razmkon A, Malek-Hosseini SA: Incidence of posttransplantation diabetes mellitus in kidney transplantation: a single-center experience. Transplant Proc 2005;37:3095-3097.
13. Hur KY, Kim MS, Kim YS, Kang ES, Nam JH, Kim SH, Nam CM, Ahn CW, Cha BS, Kim SI, Lee HC: Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients. Diabetes Care 2007;30:609-615.
14. Hagen M, Hjelmesaeth J, Jenssen T, Morkrid L, Hartmann A: A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant recipients. Nephrol Dial Transplant 2003;18:2154-2159.
15. Hjelmesaeth J, Hagen M, Hartmann A, Midtvedt K, Egeland T, Jenssen T: The impact of impaired insulin release and insulin resistance on glucose intolerance after renal transplantation. Clin Transplant 2002;16:389-396.
16. Midtvedt K, Hartmann A, Hjelmesaeth J, Lund K, Bjerkely BL: Insulin resistance is a common denominator of post-transplant diabetes mellitus and impaired glucose tolerance in renal transplant recipients. Nephrol Dial Transplant 1998;13:427-431.
17. Voytovich MH, Simonsen C, Jenssen T, Hjelmesaeth J, Asberg A, Hartmann A: Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. Nephrol Dial Transplant 2005;20:413-418.
18. Luther P, Baldwin D Jr: Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant 2004;4:2135-2138.
19. Nam JH, Mun JI, Kim SI, Kang SW, Choi KH, Park K, Ahn CW, Cha BS, Song YD, Lim SK, Kim KR, Lee HC, Huh KB: β-Cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 2001;71:1417-1423.
20. Hjelmesaeth J, Hagen M, Hartmann A, Midtvedt K, Egeland T, Jenssen T: The impact of impaired insulin release and insulin resistance on glucose intolerance after renal transplantation. Clin Transplant 2002;16:389-396.
21. Hagen M, Hjelmesaeth J, Jenssen T, Morkrid L, Hartmann A: A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant recipients. Nephrol Dial Transplant 2003;18:2154-2159.
22. Ceriello A, Motz E: Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004;24:816-823.
23. Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P: Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of lifestyle factors. Clin Chem 1997;43:1209-1214.
24. Calo L, Semplicini A, Davis PA, Bonvicini P, Cantaro S, Rigotti P, D'Angelo A, Livi U, Antonello A: Cyclosporin-induced endothelial dysfunction and hypertension: are nitric oxide system abnormality and oxidative stress involved? Transpl Int 2000;13(suppl 1):S413-S418.
25. Gross S, van Ree RM, Oterdoom LH, de Vries AP, van Son WJ, de Jong PE, Navis GJ, Zuurman MW, Bierhaus A, Gans RO, Bakker SJ: Low levels of sRAGE are associated with increased risk for mortality in renal transplant recipients. Transplantation 2007;84:659-663.
26. Tajtakova M, Petrasova D, Petrovicova J, Pytliak M, Semanova Z: Adiponectin as a biomarker of clinical manifestation of metabolic syndrome. Endocr Regul 2006;40:15-19.
27. Shen YY, Charlesworth JA, Kelly JJ, Peake PW: The effect of renal transplantation on adiponectin and its isoforms and receptors. Metabolism 2007;56:1201-1208.
28. Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D: Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 2005;20:129-134.
29. Mallamaci F, Zoccali C, Cuzzola F, Tripepi G, Cutrupi S, Parlongo S, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y: Adiponectin in essential hypertension. J Nephrol 2002;15:507-511.
30. Marcen R, Morales JM, del Castillo D, Campistol JM, Seron D, Valdes F, Anaya F, Andres A, Arias M, Bustamante J, Capdevila L, Escuin F, Gil-Vernet S, Gonzalez-Molina M, Lampreave I, Oppenheimer F, Pallardo L: Posttransplant diabetes mellitus in renal allograft recipients: a prospective multicenter study at 2 years. Transplant Proc 2006;38:3530-3532.
31. Woodward RS, Schnitzler MA, Baty J, Lowell JA, Lopez-Rocafort L, Haider S, Woodworth TG, Brennan DC: Incidence and cost of new onset diabetes mellitus among US wait-listed and transplanted renal allograft recipients. Am J Transplant 2003;3:590-598.
32. Burroughs TE, Swindle J, Takemoto S, Lentine KL, Machnicki G, Irish WD, Brennan DC, Schnitzler MA: Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation 2007;83:1027-1034.
33. Numakura K, Satoh S, Tsuchiya N, Horikawa Y, Inoue T, Kakinuma H, Togashi H, Matsuura S, Tada H, Suzuki T, Habuchi T: Incidence and risk factors of clinical characteristics, tacrolimus pharmacokinetics, and related genomic polymorphisms for posttransplant diabetes mellitus in the early stage of renal transplant recipients. Transplant Proc 2005;37:1865-1867.
34. Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM: Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001;59:732-737.
35. Marin M, Renoult E, Bondor CI, Kessler M: Factors influencing the onset of diabetes mellitus after kidney transplantation: a single French center experience. Transplant Proc 2005;37:1851-1856.
36. Prasad A, Quyyumi AA: Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 2004;110:1507-1512.